Softwr

Research · head to head

LabVantage vs Seven Bridges

LabVantage logo

LabVantage

Research

Enterprise LIMS with integrated ELN and biobanking capability

From
On request
Rated
-
Full reviewWebsite
Seven Bridges logo

Seven Bridges

Research

Cloud bioinformatics platform and trusted research environment, sold by Velsera

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: LabVantage enterprise implementation weight, with configuration and validation measured in many months; Seven Bridges the parent merged into Velsera in 2023 alongside Pierian and UgenTec, so the platform now competes for roadmap attention with clinical interpretation and diagnostics products inside a private equity owned group.
  • They diverge on capability: LabVantage covers Unified platform, Seven Bridges covers Trusted research environment.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which LabVantage and Seven Bridges actually diverge.

Attributes where LabVantage and Seven Bridges differ
AttributeLabVantageSeven Bridges
PlatformsWeb, Cloud, On-premiseWeb, API, Cloud

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in LabVantage

  • Unified platform
  • Biobanking
  • Instrument integration
  • Industry accelerators
  • Regulatory compliance
  • Web architecture

Only in Seven Bridges

  • Trusted research environment
  • Cloud-agnostic
  • CWL pipelines
  • Compliance certifications
  • Cost prediction
  • Public data commons
  • Collaboration
  • Tool library

What people use each for

The jobs each tool is most often brought in to do.

LabVantage

  • Laboratories wanting LIMS and ELN from one vendor rather than integrating twonot Seven Bridges
  • Biobanks managing specimen provenance, consent and long-term storagenot Seven Bridges
  • Pharmaceutical research organisations spanning discovery through QCnot Seven Bridges
  • Multi-site laboratory networks standardising on a single platformnot Seven Bridges

Seven Bridges

  • A cancer genomics group analysing controlled-access dbGaP data that cannot be moved to local infrastructurenot LabVantage
  • A federal or federally funded programme that needs FedRAMP Moderate authorisation for its analysis environmentnot LabVantage
  • A multi-institution consortium sharing pipelines and results under defined access controls rather than by emailing filesnot LabVantage
  • A diagnostics developer building reproducible CWL pipelines that must stand up to later regulatory reviewnot LabVantage

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

LabVantage

  • Enterprise implementation weight, with configuration and validation measured in many months
  • Pricing is quote-based with no public entry point
  • The unified platform argument only pays off for laboratories that genuinely need all four capabilities; those needing only LIMS may find focused competitors better
  • Smaller installed base than LabWare, which matters in conservative laboratory procurement
  • Industry accelerators shorten implementation but do not remove the need for laboratory-specific configuration

Seven Bridges

  • The parent merged into Velsera in 2023 alongside Pierian and UgenTec, so the platform now competes for roadmap attention with clinical interpretation and diagnostics products inside a private equity owned group.
  • Pricing is not published and splits into a platform subscription plus consumption-based cloud compute, so a heavy analysis quarter produces a bill that headcount-based budgeting does not anticipate.
  • The analysis capability itself has credible open source equivalents in Nextflow and Cromwell on raw cloud, so you are principally paying for compliance and governance rather than for the science.
  • Pipelines are built around Common Workflow Language, which is a real learning curve and a portability commitment for teams whose existing work is in other workflow languages.
  • Cloud storage of large genomic datasets accrues continuously whether or not you are analysing, and egress charges apply when moving results out, both of which are outside the subscription line.

Pricing, plan by plan

LabVantage

On request
  • LabVantage$undefined/year
    • LIMS
    • ELN
    • LES

Seven Bridges

On request
  • Seven Bridges Platform$undefined/year
    • Platform subscription quoted through Velsera sales
    • Cloud compute and storage charged on consumption on top of the subscription
    • Cost predictor tools provided to estimate analysis spend in advance

Which should you pick?

Choose LabVantage if

  • You need unified platform.
  • You work on Web, Cloud, On-premise.
  • You also want biobanking.
LabVantage review

Choose Seven Bridges if

  • You need trusted research environment.
  • You work on Web, API, Cloud.
  • You also want cloud-agnostic.
Seven Bridges review

Questions people ask

Is LabVantage or Seven Bridges better?
Neither clearly leads. LabVantage starts at On request and Seven Bridges at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, LabVantage or Seven Bridges?
LabVantage starts at On request and Seven Bridges at On request.
Does LabVantage or Seven Bridges run on more platforms?
LabVantage runs on Web, Cloud, On-premise. Seven Bridges runs on Web, API, Cloud.
What is LabVantage best used for?
LabVantage is most often used for laboratories wanting lims and eln from one vendor rather than integrating two, biobanks managing specimen provenance, consent and long-term storage, pharmaceutical research organisations spanning discovery through qc, multi-site laboratory networks standardising on a single platform. Of those, laboratories wanting lims and eln from one vendor rather than integrating two and biobanks managing specimen provenance, consent and long-term storage are not what Seven Bridges is typically brought in for.
What can LabVantage do that Seven Bridges cannot?
LabVantage covers Unified platform, Biobanking, Instrument integration, Industry accelerators. Seven Bridges covers Trusted research environment, Cloud-agnostic, CWL pipelines, Compliance certifications.

Answered from the vendors’ own pages

LabVantage: What does the unified platform actually mean?

LIMS, electronic laboratory notebook, laboratory execution and scientific data management as one product. Laboratories that would otherwise integrate and validate four vendors avoid that work.

Seven Bridges: Is Seven Bridges still sold?

Yes. It is sold by Velsera, formed in 2023 when Summa Equity merged Seven Bridges with Pierian and UgenTec. The Seven Bridges name was retained for the platform.

LabVantage: Is biobanking really different?

Yes. Specimen provenance, consent tracking and decades-long storage are distinct from test result management, and the number of platforms handling them properly is small.

Seven Bridges: What compliance does it hold?

FedRAMP Moderate, SOC 2, HIPAA, GDPR, dbGaP and ISO 27001, 27017, 27018 and 27701, which is the usual reason institutions choose it over building on raw cloud.

LabVantage: What does it cost?

Not published. Enterprise annual licensing plus implementation, quoted on scope.

Seven Bridges: How is it priced?

Not published. Expect a platform subscription plus consumption charges for cloud compute and storage.

LabVantage: Do the industry accelerators shorten implementation?

They help by supplying pre-configured workflows for a vertical. They do not remove laboratory-specific configuration or, in regulated settings, validation.

Seven Bridges: Do I have to use a specific cloud?

No. The platform is cloud-agnostic and designed to bring analysis to where the data already resides.

LabVantage: How does it compare to LabWare?

LabWare has the larger installed base and deeper pharmaceutical QC dominance. LabVantage argues on the unified LIMS and ELN platform and on biobanking. Both are enterprise projects.

Share

Related pages

More on LabVantage

More on Seven Bridges

Keep looking

Other head to heads